Loading
A phase 3 trial of Dexrazoxane, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Lenalidomide and Pegfilgrastim in Diffuse large B-cell lymphoma, run by Stichting Hemato-Oncologie voor Volwassenen Nederland, now recruiting.
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma is a phase 3 interventional study registered as NCT06220032 by Stichting Hemato-Oncologie voor Volwassenen Nederland, with 324 participants planned, started 2024-08-15 and due to reach its primary completion in 2028-12-15. Interventions recorded: Dexrazoxane, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Lenalidomide, Pegfilgrastim. Conditions recorded: DLBCL - Diffuse Large B Cell Lymphoma.
Linked to the drug Dexrazoxane because the registry names it among its interventions and Diffuse large B-cell lymphoma among its conditions. Registry record only: no result has been read by an editor.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin and the tag pipeline.
Shares Prednisone, Rituximab, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin and the tag pipeline.
Shares Prednisone, Rituximab, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Prednisone, Vincristine, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin and the tag pipeline.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin and the tag pipeline.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin and the tag pipeline.